Determinants of Direct Costs of HIV-1 Outpatient Care in Israel

Tom Rom, Itzchak Levy, Saritte Perlman, Tomer Ziv-Baran, Orna Mor*

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

Abstract

HIV-1 patients place an economic burden on the health system. The objectives of this study were to estimate the direct HIV-1 costs and cost-related factors of HIV-1 patients in Israel and identify cost predictors. We conducted a retrospective study of randomly selected HIV-1 patients aged ≥18 who visited a large outpatient clinic in 2015 and/or 2019. Yearly costs of physician and nurse visits, antiretroviral therapy (ART) and laboratory tests were calculated in USD using the 2020 purchasing power parities. Associations between disease characteristics and costs were analyzed using univariate and multivariable analysis. The median (IQR) total direct costs per patient per year were USD 12,387 (9813–14,124) and USD 12,835 (11,651–13,970) in 2015 (n = 284) and 2019 (n = 290), respectively. ART accounted for approximately 77% of all direct costs, followed by laboratory tests (20%) and medical visits (3%) in both studied years. Being female (USD +710), first yearly viral load <50 c/mL (+$1984) and ≥20 years with HIV-1 (USD +1056) were independently associated with higher costs. In conclusion, HIV-1 cost was stable in the studied period. Viral load and time since diagnosis were the major determinants associated with HIV-1 costs. ART and laboratory tests accounted for 97% of the costs. Therefore, these factors should be considered when planning future expenditures.

Original languageEnglish
Article number14542
JournalInternational Journal of Environmental Research and Public Health
Volume19
Issue number21
DOIs
StatePublished - Nov 2022

Keywords

  • HIV-1
  • Israel
  • cost-prediction
  • economic burden

Fingerprint

Dive into the research topics of 'Determinants of Direct Costs of HIV-1 Outpatient Care in Israel'. Together they form a unique fingerprint.

Cite this